Merit Medical Systems, Inc. (MMSI)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$89.60+1.16%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · MMSI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks MMSI against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Drive stable constant currency revenue growth and organic growth through product portfolio expansion and market penetration.
Stated as a priority in 4 of last 4 quarters. Revenue increased from $381.9M in 2026-Q1 to $418.8M in 2026-Q2, reflecting 9% organic, constant currency growth excluding divestitures. Management has consistently emphasized stable and improving revenue growth, and the trajectory is delivering.
“9% organic, constant currency revenue growth, excluding the impact of a strategic divestiture”
“3.7% organic, constant currency revenue growth, excluding the impact of a strategic divestiture”
“10% constant currency revenue growth and 7% organic growth”
“We have increased our 2025 revenue guidance reflecting stronger-than-expected results”
Enhance profitability through margin expansion and operational efficiencies to improve GAAP and non-GAAP operating margins.
Stated as a priority in 4 of last 4 quarters. Non-GAAP operating margin improved from 21.2% in 2025-Q2 to 22.6% in 2026-Q2, and GAAP operating margin rose from 12.3% to 14.4% over the same period. Management has consistently emphasized margin expansion, and the financial results show delivering progress.
Pursue and integrate acquisitions to expand product portfolio and market presence, including recent acquisition of View Point Medical.
Stated as a priority in 4 of last 4 quarters. The acquisition of View Point Medical was completed in 2026-Q1 and is projected to contribute $2M to $4M revenue in 2026. Management has reiterated focus on strategic acquisitions, and the acquisition is integrated and contributing to growth as planned.
“We have increased our 2026 revenue guidance reflecting the acquisition of View Point Medical”
Maintain strong cash flow generation to support operations and investments, despite acquisition-related cash outflows.
Stated as a priority in 4 of last 4 quarters. Free cash flow was $76.6M year-to-date in 2026-Q2, down 14% from prior year, reflecting acquisition and divestiture impacts. Despite fluctuations, management maintains focus on solid cash flow generation, with mixed delivery due to strategic investments.
Roll out and administer the 2026 Equity Incentive Plan to attract and retain talent aligned with shareholder interests.
Newly stated in 2026-Q2. The 2026 Equity Incentive Plan was approved and became effective on May 13, 2026, aiming to attract and retain talent. As this is a recent initiative, substantive delivery is in early stages.
Over the trailing year it converted 1.42x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
20 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“Non-GAAP operating margin increased to 22.6%, up from 21.2% year-over-year”
“Non-GAAP operating margin of 19.7%, compared to 19.3% in prior year period”
“Non-GAAP operating margin of 21.0%, compared to 19.6% in prior year period”
“We have increased our 2025 non-GAAP earnings per share guidance reflecting stronger-than-expected results”
“Acquired View Point Medical on April 1, 2026, expanding therapeutic oncology products”
“Completed acquisitions contributing to revenue growth and margin expansion”
“Management focused on strategic acquisitions to drive growth”
“Free cash flow generation of $76.6 million year-to-date, down 14%”
“Free cash flow increased 26% year-over-year to $24.7 million”
“Free cash flow generation of $74.0 million, up 13%”
“Management focused on strong free cash flow generation”